

Patent claims

1. Use of modulators of the signal transduction pathway via the protein kinase Fyn for the prophylaxis and/or treatment of tumour diseases.
5
2. Use of modulators according to claim 1 in the treatment of neuroblastomas.
- 10 3. Use according to claim 1 or 2, the modulators being inhibitors of enzymes that are directly or indirectly inhibited by active Fyn.
- 15 4. Use of modulators according to claim 1 or 2 which result in an increase in Fyn activity in the tumour cells.
- 20 5. Use of modulators according to claim 1 or 2, the modulators being inhibitors of the protein kinase CSK.
6. Use of modulators according to one of claims 1 to 4, the modulators being inhibitors of Rho-kinase.
- 25 7. Use of modulators according to one of claims 1 to 4, the modulators being inhibitors of MAP-phosphatase.
8. Use of modulators according to one of claims 1 to 4, the modulators being activators of protein kinase C.
- 30 9. Use of modulators according to claim 1 or 2 which inhibit the proteolytic degradation of Fyn-kinase *in vivo*.

10. Use of modulators according to claim 1 or 2, the modulators being inhibitors of phosphatases that antagonise Fyn.
- 5 11. Use of modulators according to claim 1 or 2 which contribute to an increase in signal transduction by Fyn.
- 10 12. Use of modulators of the signal transduction pathway via the protein kinase Fyn in the production of a medicament for the suppression of the formation of metastases of tumours in the early stage.
- 15 13. Use of modulators according to claim 9, the tumour being a paediatric or adult tumour.
14. Use of modulators according to one of the preceding claims as a constituent of a pharmaceutical
20 composition, characterised in that the composition, in addition to comprising the modulator as active ingredient, optionally comprises carrier substances and/or adjuvants.
- 25 15. Use of modulators according to one of the preceding claims, characterised in that the modulator is present in the form of a pharmacologically acceptable salt, solvate, hydrate or a pharmacologically acceptable formulation.
- 30 16. Use of modulators according to one of the preceding claims, characterised in that the modulator is present in the form of a prodrug comprising the

modulator and at least one pharmacologically acceptable protecting group which is removed under physiological conditions.

- 5 17. Use of modulators according to one of the preceding claims, characterised in that the modulator is administered orally, parenterally, rectally, by inhalation, transdermally or intranasally.